Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
PROSOM is an oral tablet small-molecule drug approved by Abbott in December 1990. The specific indication and mechanism of action are not available in current data, limiting detailed clinical characterization.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a contracting commercial organization and limited career growth opportunity.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia
Worked on PROSOM at Abbott? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
PROSOM has zero linked job openings and faces approaching LOE, making it a limited-opportunity career asset. Roles on this product are primarily focused on mature product maintenance and managed decline rather than growth initiatives.